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Abstract
Lung cancer is the leading cause of cancer death worldwide, with poor prognosis and a high rate of recurrence despite early
surgical removal. Hypoxic regions within tumors represent sources of aggressiveness and resistance to therapy. Although
long non-coding RNAs (lncRNAs) are increasingly recognized as major gene expression regulators, their regulation and
function following hypoxic stress are still largely unexplored. Combining profiling studies on early-stage lung
adenocarcinoma (LUAD) biopsies and on A549 LUAD cell lines cultured in normoxic or hypoxic conditions, we
identified a subset of lncRNAs that are both correlated with the hypoxic status of tumors and regulated by hypoxia in vitro.
We focused on a new transcript, NLUCAT1, which is strongly upregulated by hypoxia in vitro and correlated with hypoxic
markers and poor prognosis in LUADs. Full molecular characterization showed that NLUCAT1 is a large nuclear transcript
composed of six exons and mainly regulated by NF-κB and NRF2 transcription factors. CRISPR-Cas9-mediated
invalidation of NLUCAT1 revealed a decrease in proliferative and invasive properties, an increase in oxidative stress and a
higher sensitivity to cisplatin-induced apoptosis. Transcriptome analysis of NLUCAT1-deficient cells showed repressed
genes within the antioxidant and/or cisplatin-response networks. We demonstrated that the concomitant knockdown of four
of these genes products, GPX2, GLRX, ALDH3A1, and PDK4, significantly increased ROS-dependent caspase activation,
thus partially mimicking the consequences of NLUCAT1 inactivation in LUAD cells. Overall, we demonstrate that
NLUCAT1 contributes to an aggressive phenotype in early-stage hypoxic tumors, suggesting it may represent a new
potential therapeutic target in LUADs.
Introduction
Non-small cell lung cancer (NSCLC) accounts for at least
80% of lung cancer cases, with lung adenocarcinoma
(LUAD) being the most common form (~50%). Although
detection and further tumor surgical resection of early-stage
NSCLC has significantly improved the survival of patients,
~50% of patients with stage I NSCLC die within 5–10 years
[1, 2].
Hypoxia, a condition frequently encountered in solid
tumors, activates the hypoxia-inducible factor (HIF) tran-
scription complex that orchestrates the expression of a
myriad of genes, whose functions are to ensure neovascu-
larization, glucose metabolism, cell survival, tumor spread,
and resistance to most anticancer drugs [3, 4]. Not
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surprisingly, the HIF1A transcript is part of a prognostic
classifier signature of five genes in stage I LUAD [5] and
high expression of its downstream targets such as CA9
(carbonic anhydrase 9) is a predictor of worse survival [6].
Extensive evidence demonstrates that microRNAs
(miRNAs) are key components of the adaptive response to
low oxygen in tumors [7, 8]. We have notably underlined
the central role of the prototypical “hypoxamiR” miR-210
on tumor metabolic changes and on radio-resistance in lung
cancer [9, 10].
Considerable attention has recently been focused on the
emerging class of long non-coding RNAs (lncRNAs), with
more than 10,000 transcripts validated to date. LncRNAs,
defined as transcripts longer than 200 nucleotides that do
not encode proteins, are usually transcribed at lower abun-
dance than mRNAs in a tissue-specific manner and they
usually exhibit a poor primary sequence conservation [11–
13]. LncRNAs encompass pseudogenes, natural antisense
transcripts (NATs), and the long intervening non-coding
RNAs (lincRNAs). Many lncRNAs function as part of
ribonucleoprotein complexes that regulate gene expression
through diverse molecular mechanisms including recruit-
ment of transcriptional activators or repressors, chromatin
epigenetic modifications, or control of mRNA processing,
translation, or stability [13].
Integrative genomic analyses have identified lncRNAs
with a prognostic potential that may play a role in tumor
progression in four types of cancers, including lung
squamous cell carcinomas (LUSCs) [14]. Moreover,
several lncRNAs map to regions associated with disease
by genome-wide association studies and accumulating
evidence has demonstrated that they control gene net-
works that are relevant to cancer development and
metastasis [15]. Some lncRNAs regulated by hypoxia are
notably involved in metabolic adaptation and tumor
spreading [16–20].
However, only a few predicted human lncRNAs among
thousands have been well characterized for their expression
pattern, structure, precise function, and clinical significance,
especially in the context of NSCLC and of their hypoxia-
mediated aggressiveness [21–23].
In this context, we performed a comprehensive genome-
wide profiling to define hypoxia-regulated lncRNAs in a
early-stage LUAD cohort and in a LUAD cell line in vitro.
Among several “hypoxia-lncRNA” candidates, we identi-
fied NLUCAT1, a large nuclear lncRNA, which was
upregulated in hypoxic conditions in LUAD cell lines and
overexpressed in early-stage LUADs according to their
hypoxic and overall survival (OS) status. Through CRISPR-
Cas9-mediated invalidation, we demonstrated the pro-
tumoral properties of NLUCAT1 and we showed that this
transcript is associated with the regulation of cell pro-
liferation, cell invasion, and cell survival in response to
oxidative stress, and could, consequently, represent a new
target for future therapies.
Results
Genome-wide profiling of hypoxia-regulated
lncRNAs in LUAD
The identification of lncRNAs controlled by hypoxia in
LUAD was performed through a combination of profiling
approaches using microarrays enriched for lncRNA probes,
on both clinical samples and cultured cell lines. First, we
performed a transcriptomic profiling on lung samples from
57 early-stage LUAD patients (Supplementary Table S1 and
Dataset 1) that were a posteriori classified in highly, mod-
erately, and non-hypoxic groups using a metagene signature
[24]. We overall found that 775 transcripts were differen-
tially expressed between tumor and normal lung tissue, and
positively correlated with the hypoxic status of tumors,
whereas 1225 transcripts were negatively correlated with
this hypoxic status. Among these genes, 81 potential
lncRNAs were associated with the hypoxic status of the
tumors (Fig. 1a and Supplementary Table S2). In parallel,
we identified 78 predicted lncRNAs that are modulated in
hypoxic condition in the A549 LUAD cell line (Fig. 1a,
Supplementary Table S2, and Dataset 2). The comparative
analysis of these data identified three lincRNAs
(LINC00152, LUCAT1/Lnc-ARRDC3-1, Lnc-FAM113B-
5), three pseudogenes (FER1L4, GAPDHP14, TLI1P2), and
one NAT (MIF-AS1), which were upregulated by hypoxia
both in vivo and in vitro, and conversely one pseudogene,
PLAC9P1, which was repressed under oxygen deprivation
(Fig. 1a, b).
LUCAT1/Lnc-ARRDC3-1 is a new “hypoxia-lncRNA”
We focused our attention on the LUCAT1/Lnc-ARRDC3-1,
the short isoform SCAL1 of which has previously been
shown to be induced by cigarette smoke extracts in NSCLC
cell lines [25]. We showed that LUCAT1/Lnc-ARRDC3-1
expression is directly correlated with the hypoxic status of
tumors (Fig. 1c). In addition, microarray data showed that
eight out of ten probes located within this locus detected a
significant increase in LUCAT1/Lnc-ARRDC3-1 expres-
sion in A549 cells cultured under hypoxic conditions (Fig.
1d). RNA sequencing (RNA-seq) analysis of A549 cells
cultured under normoxic or hypoxic conditions also showed
reads aligned all along the genomic region of the LUCAT1/
Lnc-ARRDC3-1 locus (chr5: 90597137-90610208) and
validated induction by hypoxia (Fig. 2a). In agreement,
using distinct quantitative PCR (qPCR) assays distributed
throughout the locus, we confirmed the induction of
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LUCAT1/Lnc-ARRDC3-1 by hypoxia in two other LUAD
cell lines (Supplementary Fig. S1).
We further investigated the expression of this transcript
in RNA-seq datasets from The Cancer Genome Atlas
(TCGA) database (Supplementary Table S3). The analysis
of 535 LUAD and 502 LUSC RNA-seq profiles confirmed
that LUCAT1/Lnc-ARRDC3-1 is upregulated in relation to
the hypoxic status of tumors in LUAD and, to a lesser
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extent, in LUSC samples (Fig. 2b). This increase in
expression takes place in early-stage LUAD and LUSC with
no supplemental exacerbation in more advanced stages (Fig.
2c). We then evaluated the impact of LUCAT1/Lnc-
ARRDC3-1 expression on patient prognosis. LUAD
patients assigned to the LUCAT1/Lnc-ARRDC3-1 upper-
quartile group exhibited a statistically shorter OS time than
those in the lower-quartile group (log-rank test p= 0.0012)
(Fig. 2d).
Characterization of NLUCAT1, a large nuclear
variant of LUCAT1/Lnc-ARRDC3-1
Currently, only two short LUCAT1/Lnc-ARRDC3-1 tran-
scripts of 890 nt (LUCAT1:4) and 582 nt (LUCAT1:5),
respectively, are listed in the Refseq database (Fig. 2a).
However, as indicated, more than 20 distinct LUCAT1
predictive transcripts ranging from 212 nt to 9585 nt are
annotated in the LNCipedia database, which regroups RNA-
seq information from various sources (Broad Institute,
Gencode, NONCODE, Refseq, Ensembl…) [26]. Based on
this complex situation and on the poor definition of the
transcript boundaries frequently associated with lncRNA
sequences, we performed additional characterization of the
main LUCAT1/Lnc-ARRDC3-1 species transcribed from
this locus. Northern blot hybridizations with probes
designed in putative exons 1, 5, and 6 of LNCipedia
LUCAT1/Lnc-ARRDC3-1 annotated transcripts detected a
major ~ 10 kb band markedly stimulated by hypoxia and an
upper 12–13 kb isoform that likely corresponds to the
unspliced LUCAT1/Lnc-ARRDC3-1 pre-LncRNA (Fig.
3a). Other, less abundant transcript variants were visualized
including a faint transcript at around 900 nt that matched
with the LUCAT1:4 isoform. To precisely define the exon
composition of the main 10 kb isoform, we combined RNA-
seq and reverse transcriptase-PCR (RT-PCR) approaches
(Fig. 3b, c). We concluded that this main LUCAT1 variant
is a 9807 nt transcript constituted of six exons (Supple-
mentary Information). Moreover, we demonstrated that this
transcript is almost exclusively localized in the nuclei of
LUAD cells, with a nucleocytoplasmic ratio similar to that
of NEAT1 or MALAT1 (Fig. 4). Based on this specific
attribute, we named it NLUCAT1, for nuclear-LUCAT1.
Recent reports have shown that a large proportion of
lncRNAs are unstable [27, 28]. Hypoxia/reoxygenation
experiments and transcription inhibition with actinomycin
D demonstrated that NLUCAT1 is indeed a short-lived non-
coding transcript (half-life < 1 h), suggesting that it could
exert regulatory rather than housekeeping functions (Sup-
plementary Fig. S2).
Hypoxia mainly controls gene expression through HIF,
but also through activation of nuclear factor-κB (NF-κB)
and/or NRF2, which are involved in hypoxia-induced
inflammatory and antioxidant responses, respectively [29–
31]. To better decipher NLUCAT1 regulation after hypoxic
stress, we assessed the role of these transcription factors, as
HRE (hypoxia response elements) and also NF-κB and
NRF2 (ARE, antioxidant responsive element) consensus
binding sites were found in the promoter region of the
transcript. As expected, HIF1A inactivation by RNA
interference (RNAi) blocked induction of the hypoxic
marker CA9 but had no significant effect on NLUCAT1
expression, whereas HIF2A knockdown reduced NLU-
CAT1 induction by 30% (Supplementary Fig. S3A). Phar-
macological inhibition of NF-κB-dependent transcription
with BMS-345541 [32] totally abolished hypoxia-
dependent NLUCAT1 upregulation (Fig. S3B). Accord-
ingly, NLUCAT1 was also induced by the NF-κB-activat-
ing proinflammatory cytokine interleukin (IL)-1β in three
LUAD cell lines (Supplementary Fig. S3C). As expected,
this induction, along with that of the PTGS2 inflammatory
gene, was inhibited by BMS-345541 treatment. Finally,
small interfering RNA (siRNA)-mediated depletion of
NRF2 decreased both the basal and hypoxia-induced
expression level of NLUCAT1 by 50% (Supplementary
Fig. S3D). Chromatin immunoprecipitation (ChIP) coupled
to qPCR was then performed to assess the direct interaction
of these transcription factors with the promoter region of
NLUCAT1. For this purpose, we used data from the
ENCODE Consortium for several available human cell lines
Fig. 1 Identification of the LUAD hypoxia-regulated LncRNA sig-
nature. a Venn diagram summarizing lncRNA candidates that are
modulated by hypoxia in LUAD biopsies and in the A549 LUAD cell
line. LncRNA expression was first analyzed by microarray hybridi-
zation in 57 early-stage LUAD and 11 peritumoral healthy lung
biopsies. Tumor samples were classified by function of their hypoxic
status score and selection of hypoxia-associated lncRNAs was per-
formed using log2(intensity) > 7, absolute log2(LUAD/Healthy) > 0.7,
FDR < 0.05 and adj. P-value hypoxic status pca < 0.05. LncRNA
signature of A549 LUAD cells cultured in normoxic or hypoxic
conditions for 24 h was done using log2(intensity) > 7, absolute log2
(Hx/Nx) > 0.7 and adj. P-value < 0.05. The eight overlapping
“hypoxia-lncRNA” candidates that are both deregulated by hypoxia
in vivo and in vitro are shown. b Heatplot showing the profile of
expression of the 8 “hypoxia-lncRNA” candidates in the 57 LUAD
samples depending on their hypoxic status (High in red, No in blue).
Expression corresponds to log2 intensity followed by median center-
ing; clustering was performed using a Manhattan distance metric and
average linkage. Differential expression between normoxic and
hypoxic A549 cells is displayed as log2 fold change on the left. c
Boxplot representation of LUCAT1/Lnc-ARRDC3-1 expression in
peritumoral healthy lungs (n= 11) and in LUAD sample subsets
according to their hypoxic status (No n= 12, intermediate n= 25,
High n= 20). The results are displayed on a log2 scale. Statistical
relevance of the comparisons was determined with the Wilcoxon’s
test. d Level of expression of LUCAT1/Lnc-ARRDC3-1 transcripts
detected by the ten microarray probes spanning the LUCAT1/Lnc-
ARRDC3-1 locus in A549 cells in normoxia or hypoxia. Data are
means ± SD from two replicates. Statistically significant differences
are indicated (*p < 0.05, **p < 0.01)
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and identified several putative binding sites for these factors
in the close vicinity of histone 3 lysine 27 acetylation
(H3K27Ac) and H3K4 mono- and tri-methylation
(H3K4Me1 and H3K4Me3) marks often found near active
promoters or regulatory elements (Supplementary Fig.
S4A). In A549 cells cultured under hypoxia, we found a
Fig. 2 LUCAT1/Lnc-ARRDC3-
1 is upregulated by hypoxia
in vivo and in vitro. a
Screenshot from UCSC browser
displaying LUCAT1/Lnc-
ARRDC3-1 genomic locus on
chromosome 5, including the
Refseq and LNCipedia database
transcript annotations as well as
raw RNA-seq reads plotted for
A549 cells cultured for 24 h in
normoxic or hypoxic conditions.
b Distribution of LUCAT1/Lnc-
ARRDC3-1 expression in
LUAD and LUSC cohorts from
TCGA according to their
hypoxic status (LUAD: Healthy
n= 59, No n= 121,
Intermediate n= 311, High n=
103) (LUSC: Healthy n= 49,
No n= 52, Intermediate n=
346, High n= 104). RNA-seq
data were normalized as
described in the Materials and
Methods. The results are
displayed on a log2 scale.
Statistical differences between
samples were analyzed with the
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expression level and overall
survival of TCGA LUAD
patients by quartiles. P-values
were calculated using the log-
rank test
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Fig. 3 Structural characterization of LUCAT1/Lnc-ARRDC3-1 tran-
scripts in normoxic and hypoxic LUAD cell lines. a Northern blot
analysis of LUCAT1/Lnc-ARRDC3-1 transcripts expression in A549
cells cultured for 24 h in normoxic or hypoxic conditions. Various
[32P]-labeled cDNA probes corresponding to putative exon 1, exon 5,
and exon 6 of LNCipedia annotated LUCAT1 transcript variants were
successively hybridized on blotted RNA. RPLP0 (1229 nt) and CA9
(1561 nt) hybridizations were used as loading and hypoxic response
controls, respectively. b Screenshot from UCSC browser displaying
raw RNA-seq reads for hypoxic A549 cells (NextSeq500 Illumina
75 bp paired-end reads) plotted on LUCAT1/Lnc-ARRDC3-1 genomic
region and representation of de novo assembled ~ 10 kb LUCAT1/
Lnc-ARRDC3-1 transcript. c RT-PCR analyses of LUCAT1/Lnc-
ARRDC3-1 amplicons performed on two DNase-treated RNA pre-
parations from A549 cells cultured for 24 h under hypoxia
L. Moreno Leon et al.
significant enrichment of the more distal HRE sequence
(HRE3) in anti-HIF2A ChIP, as compared with control IgG
(Fig. S4B). A strong binding of NRF2 was also detected in
the ARE located 171 bp upstream from the transcription
start site (TSS) (Supplementary Fig. S4C). Finally, we
validated the interaction of three NF-κB family members,
RelA, c-Rel, and p50, to the more distal NF-κB-binding site
(NF-κB2) (Fig. S4D). This site was also validated for
binding RelA in cells treated with IL-1β (Fig. S4E). Thus,
we confirmed a direct interaction of the transcription factors
HIF2A, NRF2, and NF-κB with the NLUCAT1 promoter in
LUAD cells under hypoxic environment.
Taken together, these data demonstrate that NLUCAT1
is a large, unstable, hypoxia- and inflammation-sensitive
nuclear lncRNA regulated by HIF2A, NF-κB, and NRF2
transcription factors.
Targeted CRISPR-Cas9-mediated invalidation of
NLUCAT1 in LUAD cells attenuates their oncogenic
potential
To decipher the functional role of NLUCAT1, we devel-
oped a loss-of-function approach using CRISPR-Cas9-
mediated deletion of the first three exons in the A549 cell
line (Fig. 5a). After selection, individual clones were
screened for the complete deletion of the three alleles (Fig.
5b), which totally abolished NLUCAT1 transcription, as
shown by RNA-seq, northern blotting, and RNA-
fluorescent in situ hybridization (FISH) (Fig. 5a, c, d).
The consequences of NLUCAT1 knockout were then
analyzed on distinct cellular processes using several inde-
pendent clones. Cell growth was slightly but significantly
(20%) decreased in NLUCAT1-deleted clones (Fig. 6a, b).
We also found an increase in the basal production of reactive
oxygen species (ROS) in NLUCAT1-deleted cells (Fig. 6c).
Cisplatin is part of the standard first-line therapy for lung
cancer and mediates DNA damage associated with mito-
chondrial oxidative stress [33, 34]. In this context, drug
treatment produced 1.5-fold more ROS in NLUCAT1-
invalidated cells than in their wild-type (WT) counterparts
(Fig. 6c). Accordingly, mitochondrial superoxide production
was potentiated in deleted clones in the presence of cisplatin
(Supplementary Fig. S5A). Consequently, loss of NLUCAT1
expression strongly sensitized A549 cells to cisplatin-induced
apoptosis visualized by caspase-3 enzymatic assay (Fig. 6d).
This was reverted by an antioxidant treatment with N-acetyl
Fig. 4 NLUCAT1, a large nuclear variant of LUCAT1/Lnc-ARRDC3-
1. Subcellular localization of the 10 kb LUCAT1 variant was deter-
mined on A549 cells cultured in normoxic or hypoxic conditions for
24 h using: a Northern blotting: total RNAs were extracted from the
cytoplasmic (C) and nuclear (N) fractions, then separated, blotted, and
hybridized with [32P]-labeled cDNA probes for NLUCAT1 (exon 6),
LINC00152, NEAT1 (short 3756 nt variant), and MALAT1. b qPCR:
Horizontal bars represent the ratio of the expression of the indicated
lncRNAs between the nucleus and the cytosol. NEAT1 and MALAT1
are specific markers of the nuclear fraction, whereas LINC00152 is
exclusively cytoplasmic. Data are means ± SD from five independent
experiments. c Single-molecule RNA-FISH (fluorescent in situ
hybridization): cells were fixed and hybridized with NLUCAT1 and
NEAT1 ACD® probes. Nuclei were counterstained with DAPI and
cells were visualized by confocal microscopy. Scale bar corresponds to
5 µm
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cysteine (NAC) (Fig. 6d). Accordingly, NLUCAT1-deleted
cells were more sensitive to ROS-dependent apoptosis
induced by hydrogen peroxide or menadione (Supplementary
Fig. S5C). In addition, NLUCAT1 invalidation slowed down
the migratory and invasive properties of A549 cells (Sup-
plementary Fig. S5B and Fig. 6e).
Fig. 5 CRISPR-Cas9 invalidation of the LUCAT1/Lnc-ARRDC3-1
locus. a RNA-seq profile of reads mapped on the LUCAT1/Lnc-
ARRDC3-1 locus in wild-type (WT) and deleted (DEL) clones of
A549 cells under hypoxia. An illustration of the strategy used for
CRISPR-Cas9-mediated genomic deletion of the exon 1–3 region of
the LUCAT1/Lnc-ARRDC3-1 locus is shown (gRNA: Cas9 RNA
guide). b PCR analysis of the 1.7 kb genomic deletion in two WT and
two DEL clones of A549 cells. c Northern blotting analysis of
NLUCAT1 10 kb transcript expression in two WT and two DEL
clones of A549 cells under normoxic or hypoxic conditions using a
[32P]-labeled exon 6 cDNA probe. d Single-molecule RNA-FISH of
NLUCAT1 and NEAT1 in WT and DEL clones of A549 cells under
hypoxic conditions. Scale bar corresponds to 5 µm
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In a recent report, Thai et al. [25] suggested that the
siRNA-mediated knockdown of the short LUCAT1 isoform
SCAL1/LUCAT1:4 alters cell viability in the presence of
cigarette smoke extract. We showed here that this minor
isoform is cytosolic (Supplementary Fig. S6A) and con-
firmed that it is sensitive to two distinct siRNAs, whereas
the major large nuclear NLUCAT1 transcript is not affected
by this treatment (Supplementary Fig. S6B). Moreover, in
our hands, siRNA-mediated inhibition of SCAL1/
LUCAT1:4 had no impact on cell proliferation as well as on
cisplatin-induced oxidative stress and apoptosis (Supple-
mentary Fig. S6C, D, E). Furthermore, the stable re-
expression of LUCAT1:4 in CRISPR-Cas9-deleted A549
clones showed no significant effect on cell proliferation,
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ROS production, and caspase-3 activity (Supplementary
Fig. S7).
Taken together, these data clearly indicate that the major
large nuclear NLUCAT1 isoform promoted an aggressive
phenotype in LUAD, affecting the proliferative, cell survi-
val, and invasive properties of tumor cells.
Impact of NLUCAT1 invalidation on the
transcriptome of A549 cells
To gain further insight in the molecular mechanisms con-
trolled by NLUCAT1, we performed transcriptomic profil-
ing and we identified 354 genes for which the expression
was significantly altered in NLUCAT1-deleted cells com-
pared with WT clones (Fig. 7a and Supplementary Table
S4). These genes were mainly (63%) repressed in
NLUCAT1-deleted cells. According to our functional stu-
dies, gene annotation indicated that the modulated genes
were significantly associated with Gene Ontology terms
such as proliferation, invasion, apoptosis, inflammatory
response, and oxidative stress (Fig. 7a, right panel).
We further validated a subset of 28 genes in independent
experiments by qPCR (Supplementary Fig. S8A). Impor-
tantly, these genes were neither modulated by LUCAT1:4
RNAi in A549 cells nor by its stable re-expression in
CRISPR-Cas9 LUCAT1/Lnc-ARRDC3-1 locus-deleted
clones (Supplementary Fig. S8B, C), demonstrating that
the loss of short LUCAT1:4 variant expression was not
involved in the gene signature alteration observed in the
NLUCAT1 locus-deleted clones.
Among the 354 genes altered by NLUCAT1 deletion,
187 were dysregulated both in normoxic and hypoxic
conditions (Fig. 7b). Although the global hypoxic response
appeared largely unaffected by NLUCAT1 invalidation
(Fig. 7b), the transcriptome of NLUCAT1-deficient cells
revealed repressed gene networks predicted to be controlled
by the HIFIA, NRF2, and NF-κB transcription factors (Fig.
7c), suggesting that NLUCAT1 could exert a positive
feedback on these pathways. Accordingly, concerning
HIF1A, we identified 52 hypoxia-regulated genes that were
altered by NLUCAT1 invalidation (Supplementary Fig.
S9A). Most of these genes were upregulated under hypoxic
conditions in WT cells and markedly repressed in deleted
cells (Supplementary Fig. S9B, C). Among these, we
notably found the well-known hypoxia-regulated gene CA9
and the glucose transporter GLUT3 (SLC2A3) (Supple-
mentary Fig. S9C).
As NLUCAT1 knockout favored ROS production and
cisplatin-induced ROS-dependent apoptosis (Fig. 6c, d and
Supplementary Fig. S5A, C), we focused more specifically on
NRF2, which is crucial for the maintenance of oxidative
homeostasis through both hypoxia and redox signaling
[31, 35]. Among the NRF2- and/or cisplatin-regulated gene
networks, we identified four genes that were downregulated in
NLUCAT1-knockout cells: ALDH3A1 (aldehyde dehy-
drogenase 3A1), GPX2 (glutathione peroxidase 2), GLRX
(glutaredoxin), and PDK4 (pyruvate dehydrogenase kinase 4)
(Fig. 7d, Fig. S8A, Fig. 8a). Three of these genes products,
GPX2, GLRX, and PDK4, were upregulated by hypoxia in
WT cells (Fig. 8a). These enzymes either counterbalance at
different levels ROS-induced damage to proteins, lipids, and
DNA, or play a role in chemoresistance [36–40].
We demonstrated that the concomitant siRNA-mediated
knockdown of ALDH3A1, GPX2, GLRX, and
PDK4 significantly increased the production of ROS in
LUAD cells (Fig. 8b), and consequently the ROS-
dependent caspase-3 activation induced by cisplatin,
hydrogen peroxide, or menadione, thus partially mimicking
the consequences of NLUCAT1 inactivation (Fig. 8c, d).
These data indicate that the NLUCAT1-dependent reg-
ulation of these genes in LUAD cells would most likely
participate in redox signaling and maintenance of oxidative
homeostasis.
Discussion
Many lncRNAs are aberrantly expressed in cancer and are
involved as regulators at various stages of tumorigenesis
[41]. Growing evidence supports their involvement in
Fig. 6 NLUCAT1 knockout affects proliferation, ROS production,
cisplatin sensitivity, and invasion of LUAD cells. Effect of NLUCAT1
invalidation on: a cell proliferation: cells were plated (250,000/well) in
triplicate and counted at the indicated times. Data are means ± SD from
two individual WT and two individual CRISPR-Cas9 DEL clones of
A549 cells, and are representative of three independent experiments. b
Percentage of cells in S phase: cells were plated (250,000/well),
incubated for 48 h to reach exponential growth and pulsed for 4 h with
BrdU. Cells were labeled with anti-BrdU and nuclei were counter-
stained with DAPI. Data are expressed as percentage of BrdU-positive
cells determined in four independent microscope fields. Data are
means ± SD from five WT and five DEL clones of A549 cells, and are
representative of three independent experiments. c ROS production:
48 h after plating, cells (200,000) were treated or not with 20 μM
cisplatin for 24 h, then labeled with fluorescent CM-H2DCF-DA probe
and analyzed by cytometry for intracellular ROS production as indi-
cated in the Materials and Methods. Data are means ± SE from four
independent experiments performed on three WT and three DEL A549
clones. d Caspase activity: 48 h after plating, cells (200,000) were
treated or not with 20 μM cisplatin for 48 h in the presence or absence
of NAC (1 mM), then lysed and analyzed for caspase-3/7 activity as
indicated in the Materials and Methods. Data are means ± SE from
three independent experiments performed on three WT and three DEL
A549 clones. e Cell Invasion: cells (50,000) from WT or DEL clones
were seeded in serum-free medium in the upper chambers of Matrigel-
coated inserts and attracted in the lower chambers with medium con-
taining 10% FCS and 5 ng/ml EGF. After 24 h, invading cells were
scored. Data are means ± SD from two independent experiments per-
formed on three WT and three DEL A549 clones. Statistically sig-
nificant differences are indicated (*p < 0.05, **p < 0.01)
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hypoxia-regulated tumor aggressiveness. Indeed, various
lncRNAs, including NEAT1, H19, HOTAIR, and Linc-p21,
are dysregulated in response to different cellular stresses,
including hypoxia, and contribute to tumor hallmarks [20].
In the present study, we identified new “hypoxia-
lncRNAs”, eight of which were correlated with the hypoxic
status of LUADs and also modulated by hypoxia in vitro in
LUAD cell lines. We focused our attention on transcripts
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from the LUCAT1/Lnc-ARRDC3-1 locus, because (i) the
signals detected by the multiple microarray probes indicated
that this was the best candidate upregulated by hypoxia
in vivo and in vitro, (ii) it was validated as a “hypoxia-
lncRNA” in LUAD and LUSC TCGA cohorts, and (iii) its
expression was associated with lower OS.
Short-read RNA-seq profiling combined with de novo
transcript-reconstruction software has provided a first draft
of the lncRNA world, but this characterization remains
largely incomplete [42–45]. Despite curation of cDNAs and
Expressed Sequence Tags (ESTs) mainly through GEN-
CODE annotations [46, 47], information regarding tran-
script structure, in particular splice junctions and
boundaries, lacks precision. The LUCAT1 locus-associated
transcripts represent a good example of the complexity of
the lncRNA annotation situation. The LNCipedia database
proposes 25 possible transcripts, annotated
LUCAT1:1–1:25 [48]. Only one transcript has been func-
tionally annotated so far and corresponds to the 890 nt
lncRNA named LUCAT1:4/SCAL1 [25]. We first fully
characterized the sequence, structure, and subcellular loca-
lization of the different transcript(s) produced from the
LUCAT1/Lnc-ARRDC3-1 locus.
Our data confirmed the existence of the LUCAT1:4/
SCAL1 transcript in LUAD cells, but they clearly show that
this represents a minor transcript product in terms of
abundance, in both basal and hypoxic conditions. The major
transcript corresponds to a large nuclear transcript of
9807 nt with a distinct exon structure and boundaries when
compared with the 25 transcripts previously annotated so
far. We thus propose the name NLUCAT1 (which may be
also temporally annotated LUCAT1:26), but it appears to be
critical in the future to curate most of the transcripts
annotated in the different databases.
Cancer development is a complex multistep process in
which hypoxic, inflammatory, and oxidative stress respon-
ses are interconnected, notably because of significant cross-
talk between the HIF, NF-κB, and NRF2 transcription
factors [49, 50]. Inflamed tissues frequently present highly
hypoxic regions, and vice versa, which results in ROS
production [51]. HIF signaling is intricately linked to that of
NF-κB during hypoxic inflammation and oxidative stress
activates NRF2 and NF-κB, as well as HIFs, in non-hypoxic
conditions [30, 49, 52–56]. In this context, NLUCAT1
appears to be at the crossroad of these pathways, both by its
transcriptional regulation and by its functional role. Indeed,
we showed that in addition to being a “hypoxia-linc,”
NLUCAT1 is also induced by NF-κB-dependent IL-1β
proinflammatory signal. Furthermore, we demonstrated that
the hypoxia-dependent upregulation of NLUCAT1 is at
least in part dependent on NRF2 transcription factor. These
data are supported by a previous study showing that NRF2
mediates the cigarette smoke-induced expression of
LUCAT1:4/SCAL1 short variant in airway epithelial cells
[25]. In addition, LUCAT1:4/SCAL1 is repressed by RNAi-
mediated silencing of NRF2 in A549 cells and the LUCAT1
transcripts were found to be associated with the mutation
status of KEAP1 and NRF2 in LUADs and LUSCs,
respectively [57, 58].
Functional annotations of gene signature alterations
associated with NLUCAT1 loss-of-function revealed
repressed gene networks controlled by the HIF, NRF2, and
NF-κB transcription factors, suggesting that the NLUCAT1
transcript may exert a positive feedback on these pathways
by a mechanism that remains to be elucidated.
Platinum-based therapy is the first-line treatment for the
majority of NSCLC patients. The cytotoxic effects of cis-
platin are mainly mediated by DNA-damage response but
also by mitochondrial oxidative stress [33, 34]. However,
resistance to these chemotherapies is frequent and increas-
ing evidence indicates that local tumor conditions, including
a hypoxic microenvironment, may be involved [59]. We
showed that NLUCAT1 expression is increased in hypoxic
conditions. This observation is consistent with the increased
expression of LUCAT1 observed in a cisplatin-resistant
human ovarian carcinoma cell line [60]. In addition, we
showed that targeted deletion of NLUCAT1 decreased cell
proliferation and invasion, while increasing oxidative stress-
dependent sensitivity to cisplatin-induced apoptosis. By
contrast, and contrary to a previously published report using
an siRNA-based approach [61], we found that the short
variant LUCAT1:4/SCAL1 was unable to affect these
parameters. Altogether, our dataset strongly suggests that
NLUCAT1 is a member of the expanding family of
Fig. 7 NLUCAT1 invalidation alters A549 cells transcriptome in
normoxic and hypoxic conditions. a Unsupervised hierarchical clus-
tering of differentially expressed genes between three WT and three
DEL clones of A549 cells. The gene expression profiles were deter-
mined on cells cultured for 24 h in normoxic or hypoxic conditions
using pan genomic microarrays. The heat map shows the 354 genes for
which expression is statistically modulated by NLUCAT1 invalidation
based on a log2(intensity) > 6, an absolute log2(fold change) > 1, and
an adj. P-value < 0.01. Expression corresponds to log2 intensity fol-
lowed by median centering. Clustering was performed using a Man-
hattan distance metric and average linkage. Gene annotation was done
using the IPA software. b Venn diagrams comparing the distribution of
genes that are (i) altered by NLUCAT1 deletion under normoxia or
hypoxia (n= 354), or (ii) regulated by hypoxia in WT and/or DEL
cells (n= 400, log2(intensity) > 6, an absolute log2(fold change) > 1,
and an adj. P-value < 0.05). c Heatmaps of predicted upstream reg-
ulators for the comparison DEL vs. WT in normoxic or hypoxic
conditions. The red arrow indicates an inhibition of NRF2-regulated
transcripts. d Two examples of the most significant IPA NRF2- and
cisplatin-regulated gene networks altered by NLUCAT1 invalidation.
Genes repressed or upregulated in the signature are indicated in green
and red, respectively. Orange and blue indicate activation or inhibition
of the pathway, respectively
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lncRNAs such as HOTAIR, UCA1, and H19 that are
involved in platinum-based cancer drug resistance [62, 63].
We then focused on four genes of the NRF2- and/or
cisplatin-regulated networks, all of which were
downregulated in NLUCAT1-deleted cells, and which
participate in drug-resistance mechanisms or redox signal-
ing and maintenance of oxidative homeostasis to protect
cells from ROS-mediated damage. In this context, GPX2
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catalyzes the reduction of hydrogen peroxide in the cyto-
plasm, while glutathione is oxidized to glutathione disulfide
[36], thus protecting against ROS-dependent apoptosis
[64, 65]. GLRX exerts its protective role against oxidative
stress through the reduction of protein oxidation called
deglutathionylation [37, 66]. GLRX is, notably, known to
protect epithelial cells from oxidative damage via the pre-
vention of AKT glutathionylation [37, 66]. Accordingly,
GLRX downregulation could participate in the repression of
an AKT-regulated pro-survival network in NLUCAT1-
deleted cells (Fig. 7c). Our third candidate, ALDH3A1,
neutralizes highly reactive lipid peroxidation-derived alde-
hydes and attenuates ROS-mediated protein modification
and genotoxin-induced DNA damage and apoptosis
[38, 67, 68]. Interestingly, high expression of ALDH3A1 in
cancer has been associated with regulation of cell pro-
liferation and drug resistance to ROS-dependent cyclopho-
sphamide- and 5-fluorouracil-mediated cell death [68, 69].
Finally, PDK4, one of the four PDK family members, may
favor the metabolic switch to aerobic glycolysis and che-
moresistance in cancers via inhibition of the pyruvate
dehydrogenase complex [39, 40]. Knockdown or inhibition
of PDK4 reduced cell migration and invasion, while
increasing sensitivity to 5-Fluorouracil or cisplatin in colon
and/or bladder cancer cells, confirming this pro-tumorigenic
function [39, 40, 70].
In agreement with these important cancer-associated
functions, we demonstrated that the concomitant knock-
down of these four genes in LUAD cells increased ROS-
dependent apoptosis, thus partially mimicking the con-
sequences of NLUCAT1 inactivation.
Taken together, these data suggest that dysregulation of
redox signaling in NLUCAT1-deleted LUAD cells may be
likely to result from an adaptation to overcome the lack of
expression of NLUCAT1, which could slow proliferative
and invasive properties, and sensitize cancer cells to ROS-
dependent apoptosis.
Further experiments are required to fully characterize
the underlying molecular mode of action of NLUCAT1 in
LUAD. LUCAT1:4 short isoform has been proposed to
favor cell cycle progression through epigenetic silencing
of p21 and p57 cyclin-dependent kinase inhibitors due to
its association with the histone methyltransferase PRC2
(polycomb repressive complex 2) [61]. This putative
function is not consistent with our data, since in our
hands NLUCAT1 appeared rather as a negative regulator
of PRC2 signaling, as indicated in our transcriptomic
analyses with a significant positive z-score association for
EZH2 (functional enzymatic component of PRC2) in
NLUCAT1-deleted cells (Fig. 7c). Moreover, although a
large set of LincRNAs has been proposed to guide
chromatin-modifying complexes, notably PRC2, to spe-
cific genomic loci to regulate gene expression [71], recent
evidence has questioned this link, notably through the
demonstration of PRC2 promiscuous RNA binding
in vitro [72, 73]. Of note, the transcriptional repression
induced by HOTAIR is not dependent on PRC2 as pre-
viously postulated [74]. LncRNA loci can, however, also
influence the expression of neighboring genes in cis and
some can function as enhancers, termed eRNAs, stimu-
lating gene transcription by serving as the cis-regulator
[75, 76]. Histone marks obtained from ChIP-sequencing
assays on A549 cells of the ENCODE project indicate
that NLUCAT1 is transcribed from regulatory regions
enriched for H3K4me1 (mono-methylation of lysine 4 of
the H3 histone protein) and H3K27ac (acetylation of
lysine 27 of the H3 histone protein) marks (not shown)
that are predominant histone modifications found at
nucleosomes around enhancer elements. We found that
CRISPR-Cas9-mediated deletion of the NLUCAT1 TSS
region slightly repressed the expression of its neighbor-
ing gene ARRDC3 in normoxic condition but not under
hypoxia. This does not support an eRNA-mediated mode
of action but rather suggests that the deletion of a specific
DNA regulatory element located in the vicinity of
NLUCAT1 TSS influences the basal expression of
ARRDC3.
In summary, we provide evidence that NLUCAT1 is a
new hypoxia- and inflammation-driven large nuclear
lncRNA in LUAD. Targeted deletion of NLUCAT1 using a
CRISPR-CAS9 strategy in the A549 cell line revealed a
decrease in proliferative and invasive properties, an increase
in oxidative stress, and a higher sensitivity to cisplatin-
induced apoptosis, demonstrating that NLUCAT1 repre-
sents a novel coordinator of the hypoxic, inflammatory, and
antioxidant responses in LUADs.
Fig. 8 Concomitant knockdown of ALDH3A1, GPX2, GLRX, and
PDK4 partially mimics NLUCAT1 invalidation. a Western blotting
analysis of ALDH3A1, GPX2, GLRX, and PDK4 expression in A549,
WT, and DEL clones in normoxia or hypoxia. HSP60 was used as a
loading control. b, c Effect of the concomitant RNA interference of
ALDH3A1, GPX2, GLRX, and PDK4 on cisplatin-induced ROS
production and caspase activity. A549 cells were plated and trans-
fected 24 h later with 5 nM each of ALDH3A1, PDK4, GPX2, and
GLRX siRNA or 20 nM non-relevant si-NC. Forty-eight hours after
transfection, cells were treated or not with 20 μM cisplatin in the
presence or absence of NAC (1 mM) for 24 h, after which ROS pro-
duction and caspase-3/7 activity were assessed. Data are means ± SD
of duplicates from two (ROS) or six (caspase) independent experi-
ments, respectively. d Effect of the concomitant RNA interference of
ALDH3A1, GPX2, GLRX, and PDK4 on caspase activity induced by
oxidative stress: 48 h after transfection, cells were treated or not with
1 mM H2O2 or 100 μM menadione for 24 h, then lysed and analyzed
for caspase-3/7 activity. Data are means ± SD of duplicates from three
independent experiments. e, f Efficiency of concomitant RNA inter-
ference for ALDH3A1, PDK4, GPX2, and GLRX (5 nM of each) was
analyzed for transcript and protein expression 48 h after transfection.
Statistically significant differences are indicated (*p < 0.05, **p <
0.01)
L. Moreno Leon et al.
Material and methods
Cell culture and siRNA transfection
The A549, H1975, and H2228 human LUAD cell lines
were obtained from ATCC (Rockville, MD). Cells were
grown in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% fetal bovine serum (Dominique Dutscher,
Brumath, France). A triple gas incubator set at 1.2% oxy-
gen, 94% nitrogen, and 5% carbon dioxide was used for
hypoxic conditions. Cell lines were authenticated by PCR-
single-locus technology (Eurofins, Ebersberg, Germany)
and are routinely tested for mycoplasma contamination.
ON-Targetplus siRNAs (for NRF2, PDK4, GPX2,
GLRX, ALDH3A1, HIF1A, HIF2A, LUCAT1:4, and
negative control) were purchased from Dharmacon
(Lafayette, CO). Two distinct siRNAs were used for each
gene (Supplementary Table S5). Cells were plated and
transfected 24 h later at 30–50% confluency, with siRNAs
(5–10 nM), using LipofectaminTM RNAiMAX reagent
according to the manufacturer’s procedure (Thermo Fisher
Scientific, Courtaboeuf, France).
Local LUAD patient cohort used for transcriptomic
profiling
Fifty-seven LUAD patients hospitalized between 2004 and
2010 at the Pasteur Hospital (Departments of Pulmonary
Medicine and Thoracic Surgery, CHU de Nice, France)
were enrolled in this study. The diagnosis of LUAD was
based on examination of all tumor specimens using the
seventh pTNM classification and on the last histological
classification of NSCLC. Written informed consent was
obtained from participants after explaining the nature of the
study, which was approved by the research ethics board of
the Nice University hospital and was performed according
to the guidelines of the Declaration of Helsinki. The main
clinical and pathological data are summarized in Supple-
mentary Table S1. Eleven normal lung tissue specimens
were taken from areas at standard distance (3 cm) from the
same cohort of patients.
Microarray hybridization and statistical analyses
Transcriptomic analyses of LUAD samples and A549 cells
were performed on SurePrint G3 Human Gene Expression
v2 8 × 60 K microarrays from Agilent Technology (Love-
land, CO, USA) as previously described [77].
Data analyses were performed using R. We used the
Bioconductor package array QualityMetrics and custom R
scripts for quality control. Additional analyses were done
using Bioconductor package Limma. Data were normalized
using the quantile method. A linear modeling approach was
used to calculate log ratios, moderated t-statistics, and P-
values for each comparison of interest. P-values were
adjusted for multiple testing using the Benjamini–Hochberg
method that controls the false discovery rate.
First, we isolated lncRNAs that are differentially
expressed between 57 LUAD samples and 11 peritumoral
healthy lung tissues (Dataset 1). LUAD hypoxic status was
determined a posteriori based on a selection of 27 genes
extracted from a hypoxia-derived metagene signature [24]
using a score corresponding to the number of genes with a
fold change > 2 compared with the mean average expression
in healthy tissues (from 0 to 27: 0–9: “no”; 10–18: “inter-
mediate”; 19–27: “high” hypoxic). A principal component
analysis strategy using this hypoxic score was then per-
formed to calculate the correlation between hypoxia and the
log-transformed gene expression values of each probe, as
previously described [78]. Spearman’s rank correlation was
applied and probes were ranked according to p-values.
Two biological replicates were performed for compar-
ison of A549 cells cultured in normoxic and hypoxic con-
ditions (Dataset 2).
For NLUCAT1 WT and -deleted A549 clones, three
distinct clones of each phenotype cultured in normoxic or
hypoxic conditions were compared (Dataset 5). Enrichment
in biological themes (Molecular function, Upstream reg-
ulators, and canonical pathways) and biological networks
analysis were performed using Ingenuity Pathway Analysis
software (http://www.ingenuity.com/). Hierarchical cluster-
ings were performed with the MultiExperiment Viewer
(MeV) program version 4.9, using a Manhattan distance
metric and average linkage.
TCGA dataset analyses
We used LUAD and LUSC datasets from TCGA. RNA-seq
and survival data were available for 522 and 504 patients,
respectively (Supplementary Table S3). RNA-seq data were
normalized using the Bioconductor package DESeq2. The
hypoxic status for each sample was determined using the
same method as for the local cohort. Patients were separated
into high-, intermediate-, and no hypoxic status groups.
Survival curves were generated using the Kaplan–Meier
method and significance was assessed using the log-
rank test.
RNA extraction and gene expression analyses by
qPCR, RT-PCR, and northern blotting
Total RNAs were isolated with TRIzol® reagent (Thermo
Fisher Scientific) or RNAeasy kit (Qiagen, Hilden, Ger-
many) according to the manufacturer’s instructions. Gene
expression was measured by qPCR as previously
described [79] (Supplementary Table S6). For standard
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RT-PCR, genes were amplified by GoTaq DNA poly-
merase (Promega, Madison, WI, USA) using 100 ng
cDNA and analyzed on agarose gels. All primer
sequences corresponding to the different genes analyzed
are in Supplementary Table S7. Northern blotting were
done with 20 µg of total RNAs and quantified on a
Fujifilm FLA-5100 phosphorimager.
Subcellular fractionation
Cytosolic and nuclear fractions were prepared as previously
described [80], and cytosolic and nuclear RNAs were
extracted with TRIzol® and TRIzol®LS reagents (Thermo
Fisher Scientific), respectively.
Single-molecule RNA fluorescence in situ
hybridization
LncRNA-FISH was performed using RNAscope Multiplex
Fluorescent assays (Advanced Cell Diagnostics, Hayward,
CA) according to the manufacturer’s protocol. Two distinct
sets of short oligonucleotide probes were designed for
NLUCAT1: (i) a specific NLUCAT1 probe-set targeting the
3575–5860 sequence in the exon 5, and (ii) a probe-set
targeting the full-length NLUCAT1 sequence (9807 bp) that
detects NLUCAT1 and also the short LUCAT1:4 variant.
Commercially available human NEAT1 and bacterial dapB
probe sets were used as positive and negative controls,
respectively.
Chromatin immunoprecipitation
ChIP was performed using the iDeal ChIP-qPCR kit from
Diagenode (Belgium) according to the manufacturer’s
protocol. Briefly, cells were exposed to hypoxia (1% O2) or
IL-1β (20 ng/ml) and then cross-linked with ChIP cross-link
Gold reagent (Diagenode) for 30 min and 1% formaldehyde
for 15 min. Cross-linking was stopped with 0.125M gly-
cine. Cells were collected by scrapping, lysed at 4 °C, and
resuspended in shearing buffer iS1b containing protease
inhibitor cocktail. After sonication using the Bioruptor
(Diagenode) to yield DNA fragments of 200–1000 bp,
lysates were cleared by centrifugation at 16,000 × g for
10 min. For each immunoprecipitation assay, lysates cor-
responding to 4 × 106 cells were incubated with 5 μg of
rabbit antibodies pre-adsorbed on Diamag protein A-coated
magnetic beads and incubated overnight at 4 °C with
rotation.
After washing and proteinase digestion, the immuno-
precipitates were de-cross-linked 15 min at 100 °C and
genomic DNA was purified. The primers used for the
amplification of the NLUCAT1 promoter are listed in Sup-
plementary Table S8.
CRISPR-Cas9-mediated invalidation of NLUCAT1
The sequence targeted for CRISPR-Cas9 genome mod-
ification was identified using the online design tool (http://
crispr.mit.edu/). Two single-guide RNAs (sgRNAs) were
selected: gRNA1, located 172 bp upstream of the TSS of
NLUCAT1, and gRNA2, located in intron 3, 1518 bp
downstream of the TSS. Sense and antisense oligonucleo-
tides were synthesized containing the gRNA sequence, an
additional 5′-end guanine nucleotide and the BbsI over-
hangs (Supplementary Table S9). The annealed sgRNAs
were ligated into the BbsI-digested pSpCas9(BB)-2A-Puro
(pX459) V2.0 plasmid (Adgene, Cambridge, MA). Inserts
were sequenced for final validation.
A549 cells (1.8 × 106) were reverse transfected with
7.5 µg each of pX459-gRNA1 and pX459-gRNA2 con-
structs using Lipofectamine LTX® reagent (Thermo Fisher
Scientific), according to the manufacturers’ procedures.
Selection with puromycin (2 µg/ml) was performed 24 h
after transfection for at least 48 h. Cells were then cloned by
serial dilution and amplified individual clones were
screened for complete tri-allelic deletion on 50 ng genomic
DNA using three qPCR assays (Supplementary Table S10).
RNA sequencing
Solid protocol (Dataset 3)
Two micrograms of total RNAs from normoxic or hypoxic
A549 cells were depleted from ribosomal RNA with the
Ribo-Zero™ rRNA removal kit (Epicentre, Madison, WI)
and libraries were processed following the NEBNext®
mRNA Library Prep Set for SOLiD™ (New England Bio-
labs, Ipswich, MA), then amplified, quantified with the
Bioanalyzer High Sensitivity DNA Kit (Agilent), and
sequenced on SOLiD 5500XL (Thermo Fisher Scientific)
with single-end 50 bp reads. Reads were aligned to the
human genome release hg19 with the LifeScope software
v2.5.1 (Thermo Fisher Scientific) using whole tran-
scriptome pipeline for RNA‐seq libraries with default
parameters.
Illumina protocol (Dataset 4)
Libraries were generated from 500 ng of total RNA from
WT and CRISPR-Cas9-deleted A549 clones in hypoxic
conditions using the TruSeq Stranded Total RNA Library
Prep kit (Illumina, San Diego, CA) according to the man-
ufacturer’s instructions. Libraries were then quantified with
a KAPA library quantification kit (Roche, Basel, Switzer-
land) and pooled. Four nanomoles of this pool were loaded
onto a high-output flowcell and sequenced on a
NextSeq500 sequencer (Illumina) with 2 × 75 bp paired-end
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chemistry. Reads were aligned to the human genome release
hg19 using STAR v2.4.0a with default parameters.
Cloning procedures and stable lentiviral
transduction
The short 890 nt LUCAT1:4 variant (NR_103548) was
synthesized as a gBlock® double-stranded DNA fragment
(Integrated DNA Technologies, Leuven, Belgium) and
ligated into the pLJM1 vector (Addgene) between AgeI and
EcoRI sites.
Lentiviral particles were produced in 293TN cells using
the pPACKH1 HIV Lentivector Packaging Kit (System
Biosciences, Palo Alto, CA) with Lipofectamine LTX Plus
reagent according to manufacturers’ procedures. The lenti-
viral particles were then collected, mixed with PEG-it virus
precipitation kit (System Biosciences), and concentrated
100-fold. Titration of lentiviral particles was performed on
HELA cells using the Global UltraRapid™ Lentiviral Titer
Kit (System Biosciences).
A549 cells (8 × 105) were transduced with pLJM1-
LUCAT1:4 lentiviral particles (multiplicity of infection 5)
in DMEM containing 8 µg/ml polybrene. Cells were kept
under puromycin selection (2 µg/ml) 48 h after transduction
until only transduced cells remained.
ROS and superoxide production
ROS and superoxide were measured by flow cytometry with
the cell permeant 2’,7’-dichlorodihydrofluorescein diacetate
(CM-H2DCF-DA) and mitoSOX™ red fluorescent probes,
respectively (Thermo Fisher Scientific). Cells were incu-
bated in the dark with 5 µM CM-H2DCF-DA or mito-
SOX™ red in Hank’s buffered salt solution for 45 min at
37 °C, trypsinized, washed twice, and detection of oxidized
highly fluorescent 2’,7’-dichlorofluorescein or mitoSOX™
red was performed on a flow cytometer (LSR II Fortessa,
BD Biosciences) using excitation wavelengths of 488 nm
and 510 nm, respectively (emission 525 nm and 580 nm,
respectively).
Caspase assays
The activation of executioner caspase-3 in A549 cells was
determined with the Caspase-Glo 3/7 Assay kit (Promega)
according to the manufacturer’s instructions. Cells were
lysed in passive lysis buffer and the protein concentration
determined using the Pierce™ BCA Protein Assay kit
(Thermo Fisher Scientific). Cell lysates (5 μg of proteins)
were incubated with the caspase substrates and lumines-
cence was quantified after 30 min and normalized to the
amount of proteins.
Migration and invasion assays
Boyden’s chamber assays were performed as described
previously [81]. Invasion was assessed using a commer-
cially available 24-well BioCoat Matrigel Invasion Cham-
ber (BD Biosciences).
Statistical analyses
All experimental samples were included in the final ana-
lyses. Unless indicated otherwise, all data were repre-
sentative of at least two independent experiments and
expressed as means ± SD. Before statistical analysis, data
were checked for normal distribution (Shapiro–Wilk’s test)
and comparable variance (F-test for equality of variances for
data with normal distribution). Comparisons between two
groups of normally distributed data with equal variances
were performed using the unpaired two-sided Student’s t-
test. Differences were considered statistically significant at
p < 0.05. Sample size (n), statistical tests, and p-values are
indicated in the figure legends.
Antibodies
For ChIP experiments, rabbit anti-HIF-2α (ab199) was from
Abcam (Cambridge, UK), normal rabbit IgG and rabbit
anti-NRF2 (D179C-XP) were from Cell Signaling Tech-
nology (Danvers, MA, USA), and rabbit polyclonal anti-
dodies to RelA (sc-372), NF-κB p50 (sc7178x), and c-Rel
(sc-71 ×) were from Santa Cruz Biotechnology (Heidelberg,
Germany). For western blotting analyses, goat polyclonal
antibody to Hsp60 (sc-1052) and mouse monoclonal anti-
bodies to GLRX (sc-293250) and ALDH3A1 (sc-376089)
were purchased from Santa Cruz Biotechnology. Anti-
PDK4 (AP7041B) was from Abgent (San Diego, CA, USA)
and anti-GPX2 (GTX100292) from GeneTex (Irvine, CA,
USA). Secondary horseradish peroxidase-conjugated anti-
bodies were from Dako (Copenhagen, Denmark).
Data availability
The experimental data from microarray and RNA sequen-
cing have been deposited in the NCBI Gene Expression
Omnibus (GEO) database under SuperSerie GSE117049
containing 5 distinct datasets.
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